Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein

Journal of Nuclear Medicine

Volumn 56, Issue 5, 2015, Pages 701-706

  Lyoo, Chul Hyoung ^a,b   Ikawa, Masamichi ^b   Liow, Jeih San ^b   Zoghbi, Sami S ^b   Morse, Cheryl L ^b   Pike, Victor W ^b   Fujita, Masahiro ^b   Innis, Robert B ^b   Kreisl, William Charles ^b,c  

^a Yonsei University College of Medicine   (South Korea)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

11C PBR28; Alzheimer disease; Neuroinflammation; Positron emission tomography; Ratio method

Indexed keywords

CARBON PBR28 C 11; CARRIER PROTEIN; RADIOLIGAND; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; (METHYL-(11)C)N-ACETYL-N-(2-METHOXYBENZYL)-2-PHENOXY-5-PYRIDINAMINE; 4 AMINOBUTYRIC ACID RECEPTOR; LIGAND; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; TSPO PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG PROTEIN BINDING; DRUG UPTAKE; FEMALE; HUMAN; MALE; NERVOUS SYSTEM INFLAMMATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; RECEPTOR BINDING; STANDARDIZED UPTAKE VALUE RATIO; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; DIAGNOSTIC USE; INFLAMMATION; METABOLISM; MIDDLE AGED; SCINTISCANNING; STANDARD;

AGED; ALZHEIMER DISEASE; CEREBELLUM; FEMALE; HUMANS; INFLAMMATION; LIGANDS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRIMIDINES; RECEPTORS, GABA; REFERENCE STANDARDS;

EID: 84929497475     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.146027     Document Type: Article

References (25)

1. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair. Pharmacol Ther. 2008;118:1-17.
2. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain. 2013;136:2228-2238.
3. 11C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab. 2014;34:989-994.
4. 11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48:158-167.
5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-259.
6. Mattiace LA, Davies P, Yen SH, Dickson DW. Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathol. 1990;80:493-498.
7. Wood PL. The Cerebellum in AD. In: Wood PL, ed. Neuroinflammation. Totowa, New Jersey: Humana Press; 2003:295-300.
8. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-269.
9. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270-279.
10. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab. 2013;33:53-58.
11. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
12. Fujita M, Imaizumi M, Zoghbi SS, et al. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage. 2008;40:43-52.
13. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B. 1995;57:289-300.
15. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab. 2012;32:1-5.
16. 18F]-FEPPA. J Cereb Blood Flow Metab. 2012;32:968-972.
17. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN. Identifying improved TSPO PET imaging probes through biomathematics: the impact of multiple TSPO binding sites in vivo. Neuroimage. 2012;60:902-910.
18. Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011;52:24-32.
19. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev. 1999;51:629-650.
20. 11C]DPA-713 PET in individuals infected with HIV. J Neurovirol. 2014;20:219-232.
21. Jučaite A, Cselenyi Z, Arvidsson A, et al. Kinetic analysis and test-retest variability of the radioligand [11 C](R)-PK11195 binding to TSPO in the human brain: a PET study in control subjects. EJNMMI Res. 2012;2:15.
22. 11C]PK11195 studies in Alzheimer's disease and mild cognitive impairment. J Cereb Blood Flow Metab. 2007;27:1965-1974.
23. 11C]DAA1106. Biol Psychiatry. 2008;64:835-841.
24. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56-62.
25. in 't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.